Genetic variant rs10251977 (G>A) in EGFR-AS1 modulates the expression of EGFR isoforms A and D
Abstract Tyrosine kinase inhibitor is an effective chemo-therapeutic drug against tumors with deregulated EGFR pathway. Recently, a genetic variant rs10251977 (G>A) in exon 20 of EGFR reported to act as a prognostic marker for HNSCC. Genotyping of this polymorphism in oral cancer patients showed...
Guardado en:
Autores principales: | Shankar Dhamodharan, Mathew Maria Rose, Sundaram Reddy Chakkarappan, Karuppiah Vijayamuthuramalingam Umadharshini, Ramalingam Arulmurugan, Shanmugam Subbiah, Ituro Inoue, Arasambattu Kannan Munirajan |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/faff5b05fc5f4e8b8985d90024ca286f |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
LncRNA OIP5-AS1 is overexpressed in undifferentiated oral tumors and integrated analysis identifies as a downstream effector of stemness-associated transcription factors
por: Ganesan Arunkumar, et al.
Publicado: (2018) -
EGFR soluble isoforms and their transcripts are expressed in meningiomas.
por: Angélique Guillaudeau, et al.
Publicado: (2012) -
Combination of EGFR-TKIs with chemotherapy versus chemotherapy or EGFR-TKIs alone in advanced NSCLC patients with EGFR mutation
por: Wen M, et al.
Publicado: (2018) -
Including total EGFR staining in scoring improves EGFR mutations detection by mutation-specific antibodies and EGFR TKIs response prediction.
por: Shang-Gin Wu, et al.
Publicado: (2011) -
Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer
por: Beth O. Van Emburgh, et al.
Publicado: (2016)